Use of pharmacodynamic principles to inform β-lactam dosing: "S" does not always mean success.
暂无分享,去创建一个
[1] G. Drusano,et al. Pharmacokinetic-pharmacodynamic considerations in the design of hospital-acquired or ventilator-associated bacterial pneumonia studies: look before you leap! , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[2] D. Nicolau,et al. Length of Stay and Hospital Costs Associated with a Pharmacodynamic‐Based Clinical Pathway for Empiric Antibiotic Choice for Ventilator‐Associated Pneumonia , 2010, Pharmacotherapy.
[3] D. Nicolau,et al. Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia. , 2010, Journal of critical care.
[4] D. Paterson,et al. A systematic review on clinical benefits of continuous administration of &bgr;-lactam antibiotics* , 2009, Critical care medicine.
[5] M. Kinzig,et al. Penetration of Meropenem into Epithelial Lining Fluid of Patients with Ventilator-Associated Pneumonia , 2011, Antimicrobial Agents and Chemotherapy.
[6] F. Scaglione,et al. Pharmacokinetics/pharmacodynamics of antibacterials in the Intensive Care Unit: setting appropriate dosing regimens. , 2008, International journal of antimicrobial agents.
[7] Stephan Schmidt,et al. PK/PD: new insights for antibacterial and antiviral applications. , 2008, Current opinion in pharmacology.
[8] Qun Du,et al. In Vitro Evaluation of CBR-2092, a Novel Rifamycin-Quinolone Hybrid Antibiotic: Microbiology Profiling Studies with Staphylococci and Streptococci , 2008, Antimicrobial Agents and Chemotherapy.
[9] V. Tam,et al. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[10] Aryun Kim,et al. Optimal Dosing of Piperacillin‐Tazobactam for the Treatment of Pseudomonas aeruginosa Infections: Prolonged or Continuous Infusion? , 2007, Pharmacotherapy.
[11] D. Nicolau,et al. Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessment. , 2007, Diagnostic microbiology and infectious disease.
[12] J. Burke,et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Guidelines for Developing an Institutional Program to Enhance Antimicrobial Stewardship , 2007 .
[13] G. Drusano,et al. Application of Antimicrobial Pharmacodynamic Concepts into Clinical Practice: Focus on β‐Lactam Antibiotics , 2006 .
[14] Vincent H. Tam,et al. Optimization of Meropenem Minimum Concentration/MIC Ratio To Suppress In Vitro Resistance of Pseudomonas aeruginosa , 2005, Antimicrobial Agents and Chemotherapy.
[15] B. Corrigan,et al. How Modeling and Simulation Have Enhanced Decision Making in New Drug Development , 2005, Journal of Pharmacokinetics and Pharmacodynamics.
[16] M. Kollef,et al. Pseudomonas aeruginosa Bloodstream Infection: Importance of Appropriate Initial Antimicrobial Treatment , 2005, Antimicrobial Agents and Chemotherapy.
[17] G. Drusano,et al. Pharmacodynamic Profiling of Piperacillin in the Presence of Tazobactam in Patients through the Use of Population Pharmacokinetic Models and Monte Carlo Simulation , 2004, Antimicrobial Agents and Chemotherapy.
[18] G. Drusano. How does a patient maximally benefit from anti-infective chemotherapy? , 2004, Clinical Infectious Diseases.
[19] Ronald N. Jones,et al. Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001). , 2004, International journal of antimicrobial agents.
[20] George L. Drusano,et al. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug' , 2004, Nature Reviews Microbiology.
[21] J. Rex,et al. Pharmacokinetic/pharmacodynamic modeling can help guide targeted antimicrobial therapy for nosocomial gram-negative infections in critically ill patients. , 2004, Diagnostic microbiology and infectious disease.
[22] O. Cars,et al. Postantibiotic, Postantibiotic Sub-MIC, and Subinhibitory Effects of PGE-9509924, Ciprofloxacin, and Levofloxacin , 2003, Antimicrobial Agents and Chemotherapy.
[23] W. Craig,et al. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. , 1996, The Pediatric infectious disease journal.
[24] W. Craig. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. , 1995, Diagnostic microbiology and infectious disease.
[25] G. Drusano,et al. Postantibiotic effect of imipenem on Pseudomonas aeruginosa , 1984, Antimicrobial Agents and Chemotherapy.
[26] G. Rolinson,et al. Effect of protein binding on antibiotic activity in vivo. , 1983, The Journal of antimicrobial chemotherapy.
[27] P. McDonald,et al. Enhancement of leukocyte activity against Escherichia coli after brief exposure to chloramphenicol , 1979, Antimicrobial Agents and Chemotherapy.
[28] A. Novelli,et al. Pharmacokinetic and Pharmacodynamic Parameters of Antimicrobials , 2009, Clinical pharmacokinetics.
[29] A. Kumar. Piperacillin-Tazobactam for Pseudomonas aeruginosa Infection: Clinical Implications of an Extended-Infusion Dosing Strategy , 2008 .
[30] Alan Forrest,et al. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[31] G. Drusano,et al. Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists. , 2006, Pharmacotherapy.
[32] Ronald N. Jones,et al. Results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme: report of the 2001 data from 15 United States medical centres. , 2004, International journal of antimicrobial agents.
[33] I. Odenholt. Pharmacodynamic effects of subinhibitory antibiotic concentrations. , 2001, International journal of antimicrobial agents.
[34] W. Craig,et al. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[35] O. Cars,et al. The post-antibiotic sub-MIC effect in vitro and in vivo. , 1993, The Journal of antimicrobial chemotherapy.
[36] M. Derriennic,et al. Dirithromycin in the treatment of skin and skin structure infections. , 1993, The Journal of antimicrobial chemotherapy.
[37] P. McDonald,et al. Postantibiotic leukocyte enhancement: increased susceptibility of bacteria pretreated with antibiotics to activity of leukocytes. , 1981, Reviews of infectious diseases.